C22.0 C78.7
Conditions
Interventions
Group 1: Amounts of radioactivity are measured in the urine and faeces of patients who underwent a radioembolisation planning procedure with Ho-166 microspheres for 24 h after the procedure. Amounts o
Sponsors
Universitätsklinikum Jena
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with primary (HCC, CCC) and secondary (metastases) malignant liver tumors may undergo SIRT, depending on previous treatments, other clinical, laboratory and imaging data.
Exclusion criteria
Exclusion criteria: Patients with SIRT contraindications (e.g. high tumor load, impaired liver function)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the renal and intestinal excretion of Holmium-166 during the first 48h after application of the Scout Dose and after application of the treatment dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| To gain experience using the Holmium Scout Dose, to evaluate the side effect profile of this and of the SIRT with QuiremSpheres. A potential sub-project would be to measure to radiation exposure to the nuclear medicine physician and the radiologist during the procedures. | — |
Countries
Germany
Contacts
Public ContactRobert Drescher
Klinik für Nuklearmedizin, Uniklinikum Jena
Outcome results
None listed